Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis

Current therapies for inflammatory bowel disease (IBD), such as olsalazine and cyclosporine, often exhibit limited long-term efficacy and are associated with adverse effects. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, shows promise for its anti-inflammatory properties, though its effect...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of molecular sciences Ročník 26; číslo 16; s. 7913
Hlavní autori:	Thapa, Dinesh, Patil, Mohan, Warne, Leon N., Carlessi, Rodrigo, Falasca, Marco
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI AG 16.08.2025 MDPI
Predmet:	Animals Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use B cells Cannabidiol Cannabidiol - pharmacology Cannabidiol - therapeutic use Colitis Colitis - chemically induced Colitis - drug therapy Colitis - metabolism Colitis - pathology Colon - drug effects Colon - metabolism Colon - pathology Combination therapy Cyclosporine Cyclosporine - pharmacology Cyclosporine - therapeutic use Cytokines Cytokines - metabolism Dextran Dextran Sulfate Diarrhea Disease Models, Animal Drug Therapy, Combination Gastrointestinal diseases Glucagon Glucagon-Like Peptide 1 - metabolism Health aspects Inflammation Inflammatory bowel disease Kinases Liver Male Medical research Medicine, Experimental Mesalamine - pharmacology Mesalamine - therapeutic use Mice Olsalazine Pain Pathogenesis Patient compliance Peptides Peroxidase - metabolism Proteins Remission (Medicine) Tumor necrosis factor-TNF Australia United States Illinois cannabidiol cyclosporine olsalazine inflammation DSS-induced colitis combination therapy IBD cytokines
ISSN:	1422-0067, 1661-6596, 1422-0067
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Current therapies for inflammatory bowel disease (IBD), such as olsalazine and cyclosporine, often exhibit limited long-term efficacy and are associated with adverse effects. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, shows promise for its anti-inflammatory properties, though its effectiveness as a monotherapy remains inconclusive. This study investigates the therapeutic potential of combining low-dose CBD (10 mg/kg) with olsalazine (50 mg/kg) or cyclosporine (2.5, 5 mg/kg) in dextran sulphate sodium (DSS)-induced acute and chronic colitis models in mice. Disease severity was assessed via disease activity index (DAI), colon morphology, cytokine and chemokine expression, myeloperoxidase (MPO) activity, systemic inflammatory markers, and glucagon-like peptide-1 (GLP-1) regulation. Safety evaluations included haematology and plasma biochemistry. DSS-treated mice showed elevated DAI scores, colon shortening, heightened inflammation, and organ enlargement. Combination therapies significantly ameliorated colitis, reducing DAI, MPO activity, and inflammatory cytokines, while restoring colon length and GLP-1 levels—without inducing liver or kidney toxicity. These findings demonstrate that combining a low dose of CBD with standard IBD drugs enhances therapeutic efficacy while minimizing side effects, supporting its integration into future combination strategies for more effective and safer IBD management.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1422-0067 1661-6596 1422-0067
DOI:	10.3390/ijms26167913